The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized, double-blinded, phase II trial of a WT1 peptide vaccine as adjuvant therapy in patients with malignant pleural mesothelioma (MPM).
L. M. Krug
No relevant relationships to disclose
A. S. Tsao
No relevant relationships to disclose
S. Kass
No relevant relationships to disclose
V. W. Rusch
No relevant relationships to disclose
W. D. Travis
No relevant relationships to disclose
K. Panageas
No relevant relationships to disclose
P. S. Adusumili
No relevant relationships to disclose
M. G. Kris
No relevant relationships to disclose
P. G. Maslak
No relevant relationships to disclose
D. A. Scheinberg
No relevant relationships to disclose